Download - Glenmark

More documents

Recommendations

Info

Schedules annexed to and forming part of the Financial Statements (All amounts in millions of Indian Rupees, unless otherwise stated) 12. MANAGERIAL REMUNERATION 2010-2011 2009-2010 (a) Paid/payable to directors* Salaries, perquisites and other benefits 40.47 23.82 Commission 3.24 0.96 Sitting fees 0.80 0.72 Contribution to provident fund and superannuation fund 10.58 11.11 55.09 36.61 Name of Directors 1. Mr. Gracias Saldanha 0.06 0.12 2. Mrs. B. E. Saldanha 0.08 0.06 3. Mr. Glenn Saldanha 32.25 18.28 4. Mrs. Cheryl Pinto 12.10 9.41 5. Mr. A. S. Mohanty 9.94 8.20 6. Other Directors 0.66 0.54 * Excludes contributions to Gratuity and Leave Encashment Fund, which is based on actuarial valuation. (b) Computation of net profits in accordance with Section 349 and Section 309(5) of the Companies Act, 1956. Profit before taxation as per statement of profit and loss 2,508.10 1,210.13 Add: Depreciation as per statement of profit and loss 209.88 212.78 Provision for doubtful debts 15.00 17.50 2,732.98 1,440.41 Less: Depreciation calculated under Section 350 of the Companies Act, 1956 209.88 212.78 Net profit in accordance with Section 349 of the Companies Act, 1956 2,523.10 1,227.63 Add: Managerial remuneration paid/payable to directors 55.09 36.61 Net profit in accordance with Section 309(3) of the Companies Act, 1956 2,578.19 1,264.24 Maximum managerial remuneration allowed under Section 198 of the Companies Act, 1956, 11 per cent of the above 283.60 139.07 13. CAPACITY, PRODUCTION, SALES AND STOCKS (a) Capacities and actual production (including samples) Installed Capacity Actual Production Class of goods UoM 2010-2011 2009-2010 2010-2011 2009-2010 Injections Ltrs - - 150,119 210,901 Liquid Orals Ltrs 8,553,666 8,553,666 4,825,608 4,175,057 Lotions and Externals Ltrs 870,025 870,025 686,220 708,052 Ointments and Creams Kgs 1,153,500 1,136,550 731,372 834,457 Solids and Powders Kgs 113,000 113,000 286,185 311,173 Tablets and Capsules Nos 1,182,950,000 1,182,950,000 760,097,746 784,299,349 Aerosol Spray Nos 3,000,000 - 357,213 - Inhaler Capsules Nos 400,000 - 198,558 - Others - - 60,142 132,131 Note: (i) The products of the Company are exempt from licencing procedures. (ii) Installed capacity, being a technical matter, has not been verified by the auditors. However, the management has certified the same. (iii) Actual production includes goods manufactured at third party manufacturing facilities on loan licence basis and at leased facilities. 72 GLENMARK PHARMACEUTICALS LIMITED
Schedules annexed to and forming part of the Financial Statements (All amounts in millions of Indian Rupees, unless otherwise stated) (b) (c) (d) (e) Sales 2010-2011 2009-2010 Class of goods UoM Qty Value Qty Value Injectibles Ltrs 266,716 1,071.16 360,800 674.56 Liquid Orals Ltrs 4,910,763 1,749.09 4,464,608 1,411.50 Lotions and Externals Ltrs 735,221 1,284.49 845,595 1,033.32 Ointments and Creams Kgs 722,993 2,003.35 872,132 2,016.11 Solids and Powders Kgs 282,505 173.91 316,939 166.08 Tablets and Capsules Nos 1,150,662,316 5,056.41 1,124,223,930 4,153.83 Aerosol Spray Nos 300,975 46.05 - - Inhaler Capsules Nos 124,151 12.72 - - Cardiac diagnostic services - 16.72 - 15.29 Others 708.58 826.18 TOTAL 12,122.48 10,296.87 1. Sales are net of sales returns. 2. Sales quantities does not include free issues, samples and breakages. Finished goods purchased (includes samples) 2010-2011 2009-2010 Class of goods UoM Qty Value Qty Value Injectibles Ltrs 94,737 184.97 151,626 241.78 Liquid Orals Ltrs 139,690 50.92 137,390 45.54 Lotions and Externals Ltrs 35,447 18.12 100,869 41.75 Ointments and Creams Kgs 12,513 8.67 17,347 16.79 Tablets and Capsules Nos 365,389,824 561.38 322,750,466 436.83 Others 47.52 58.81 TOTAL 871.58 841.50 Raw and packing materials consumed 2010-2011 2009-2010 Products UoM Qty Value Qty Value Cefuroxime Axetil USP Kgs 2,733 28.29 2,510 25.04 Linezolid IH Kgs 2,374 40.63 1,560 31.20 Mupirocin USP Kgs 376 53.35 316 49.09 Propylene Glycol IP Kgs 387,926 38.74 366,813 33.32 Sugar S/30 IH Kgs 1,763,619 54.42 1,461,206 49.84 Sorbitol Solution 70% IP Kgs 870,701 30.09 809,886 25.02 Clarithromycin USP Kgs 1,946 24.28 1,264 13.00 Telmisartan Kgs 8,897 79.55 7,363 95.31 100ML Amber Pet Bottles (25 MM Neck) Nos 31,202,724 54.69 28,442,845 46.04 Sertaconazole Nitrate BP Kgs 436 26.69 - - Others 1,949.13 1,634.93 TOTAL 2,379.86 2,002.79 Break-up of materials and consumable stores consumed 2010-2011 2009-2010 Value Per cent Value Per cent Materials Imported materials 91.70 3.85 76.62 3.83 Indigenously procured 2,288.16 96.15 1,926.17 96.17 2,379.86 100.00 2,002.79 100.00 Consumable stores and spares Imported - - - - Indigenously procured 59.52 100.00 42.27 100.00 59.52 100.00 42.27 100.00 Annual Report 2010-2011 73
Page 35 and 36: Profiles of Directors Mr. Gracias S
Page 37 and 38: DIRECTORS Mr. D. R. Mehta, Mrs. B.
Page 39 and 40: 3. Metformin ER Tablets 1000 mg 4.
Page 41 and 42: ANNEXURE - B Disc losure in the Dir
Page 43 and 44: Report on Corporate Governance Purs
Page 45 and 46: 5. Shareholders’/Investors’ Gri
Page 47 and 48: Distribution Schedule as on 31 Marc
Page 49 and 50: Market Price Data: High, low during
Page 51 and 52: Certification by the Chief Executiv
Page 53 and 54: Auditors’ Report To, The Members
Page 55 and 56: (b) The dues outstanding in respect
Page 57 and 58: Profit and Loss Account (All amount
Page 59 and 60: Cash Flow Statement (All amounts in
Page 61 and 62: Schedules annexed to and forming pa
Page 75: Schedules annexed to and forming pa
Page 81 and 82: Additional information as required
Page 83 and 84: Consolidated Statement of Financial
Page 85 and 86: Consolidated Statement of Comprehen
Page 87 and 88: Notes to Consolidated Financial Sta
Page 89 and 90: the foreign entity and translated i
Page 91 and 92: The Group’s internal drug develop
Page 93 and 94: Financial liabilities are recognise
Page 95 and 96: In those cases where the possible o
Page 97 and 98: NOTE B - BASIS OF CONSOLIDATION The
Page 99 and 100: NOTE H - PROPERTY, PLANT AND EQUIPM
Page 101 and 102: Working Capital Facilities is secur
Page 103 and 104: NOTE R - MATERIALS CONSUMED Materia
Page 105 and 106: Net compensated absence cost for th
Page 107 and 108: NOTE Y - SEGMENT REPORTING The Chie
Page 109 and 110: The Group’s trade and other recei
Page 111 and 112: As at 31 March 2011, the Group’s
Page 113 and 114: Depreciation Further, depreciation
Page 116 and 117: GLENMARK PHARMACEUTICALS LIMITED Re
Page 118: GLENMARK PHARMACEUTICALS LIMITED Re

Download - Glenmark

Create successful ePaper yourself

Delete template?

Save as template?